2616 CStone Pharmaceuticals HKEX · China

CStone Pharmaceuticals (2616) news

CStone Pharmaceuticals is a public biotech or pharmaceutical company listed on HKEX under the ticker 2616, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest CStone Pharmaceuticals news

We have not published a story on CStone Pharmaceuticals yet. When there is news, it will appear here.

Questions about CStone Pharmaceuticals

What is the ticker symbol of CStone Pharmaceuticals?

CStone Pharmaceuticals trades under the ticker 2616 on HKEX.

Where is CStone Pharmaceuticals listed?

CStone Pharmaceuticals is listed on HKEX. Our directory also records these other listings: GETTEX:PH4; LS:A2PEFW.

Which country or territory is CStone Pharmaceuticals listed under?

Our directory records CStone Pharmaceuticals under China.

What does CStone Pharmaceuticals do?

Our directory classifies CStone Pharmaceuticals as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of CStone Pharmaceuticals?

The ISIN recorded for CStone Pharmaceuticals is KYG2588M1006.

Does aibio.space cover CStone Pharmaceuticals?

aibio.space lists CStone Pharmaceuticals among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to CStone Pharmaceuticals?

Companies in our directory listed in the same country and business area as CStone Pharmaceuticals: Guizhou Bailing Group Pharmaceutical Co., Mabwell (Shanghai) Bioscience Co., Jilin Jian Yisheng Pharmaceutical Co., Ascentage Pharma Group International, North China Pharmaceutical Company, Tianjin Chase Sun Pharmaceutical Co..

Investor discussion: CStone Pharmaceuticals

Members talk about CStone Pharmaceuticals (2616). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CStone Pharmaceuticals, newest first. Each line links the filing it comes from.

Jun 1, 2026Financings
Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR, PROPOSED GRANT OF SHARE OPTIONS AND RSUS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP AND THE POST-IPO RSU SCHEME AND NOTICE OF ANNUAL GENERAL MEETING. Source
Apr 22, 2026Financings
Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Apr 14, 2026Financings
Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Jul 16, 2025Financings
Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Jul 9, 2025Financings
Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Jun 3, 2025Financings
Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING. Source
Apr 10, 2025Financings
Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Apr 2, 2025Financings
Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

Press releases

Headlines of CStone Pharmaceuticals's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 25, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES MAJOR CLINICAL VALIDATION MILESTONE FOR CS2009 AT ESMO 2026: DATA FROM MORE THAN 300 PATIENTS SUPPORT MECHANISM, SAFETY AND BROAD ANTITUMOR ACTIVITY
Sep 24, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 496,000 SHARES, WITH ACCUMULATED PURCHASE TOTALING 14,210,500 SHARES
Sep 7, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - THE COMPANY INCLUDED IN SOUTHBOUND STOCK CONNECT
Aug 27, 2026HKEXnews
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026
Aug 20, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - NMPA IND APPROVAL FOR CS5007 (EGFR/HER3 BISPECIFIC ADC) IN CHINA
Jul 22, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - PROGRESS ON JOINT SHARE PURCHASE BY THE DIRECTORS AND SENIOR MANAGEMENT AND ON-MARKET SHARE REPURCHASE
Jul 20, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ESMO 2026 PREVIEW | UPDATED DATA FURTHER VALIDATE THE CLINICAL POTENTIAL AND GLOBAL DEVELOPMENT PROSPECTS OF CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY)
Jun 25, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - CSTONE PHARMACEUTICALS ENTERS INTO EXCLUSIVE COMMERCIALIZATION AGREEMENT WITH ARROTEX FOR SUGEMALIMAB ACROSS AUSTRALIA AND NEW ZEALAND
Jun 23, 2026HKEXnews
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 23, 2026
Jun 16, 2026HKEXnews
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CIRCULAR OF THE ANNUAL GENERAL MEETING
Jun 11, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INITIATION OF GLOBAL PHASE I TRIAL OF CS5007 (EGFR/HER3 BISPECIFIC ADC)
Jun 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - JOINT SHARE PURCHASE PLAN INITIATED BY THE DIRECTORS AND SENIOR MANAGEMENT
Jun 1, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Jun 1, 2026HKEXnews
PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR, PROPOSED GRANT OF SHARE OPTIONS AND RSUS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP AND THE POST-IPO RSU SCHEME AND NOTICE OF ANNUAL GENERAL MEETING
Jun 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ASCO 2026 | CSTONE PRESENTS LATEST CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY) CLINICAL DATA
May 13, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
May 11, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - CSTONE INITIATES NATIONWIDE COMMERCIAL SUPPLY OF LOCALLY MANUFACTURED PRALSETINIB CAPSULES
Apr 22, 2026HKEXnews
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Apr 22, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ASCO 2026 PREVIEW: CSTONE TO PRESENT UPDATED CLINICAL DATA FOR CS2009 (PD 1/VEGF/CTLA 4 TRISPECIFIC ANTIBODY)
Apr 20, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTED PRECLINICAL DATA FOR THREE NOVEL OR DIFFERENTIATED ADCS AT AACR 2026, INCLUDING CS5007 (EGFR/HER3)

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2616 on TradingView.

Listing details

Company: CStone Pharmaceuticals
Ticker: 2616
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: KYG2588M1006
Other listed symbols: GETTEX:PH4; LS:A2PEFW
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction